The market of the wearable injectors is experiencing profound changes in line with the growing use of newer and highly efficient drug delivery tools and the need for simpler and more patient-centered approaches to pain management. One of the major tendencies is the increasing preference toward subcutaneous and wearable injectors by the patients who self-administer their drugs. With the help of these devices, people who require a particular drug can now do the job at home, thereby limiting the frequency of visits to medical institutions. This is particularly relevant in chronic disease management where patients can have greater influence in work with their healthcare providers on their treatment routes, therefore ensuring adhering to their regimens and improving health overall.
As well, the smart and connected wearable injectors are being brought into the vogue. These devices are embedded with the connectivity functions enabling patients, and doctors to be tracked for medication adherence, dosage history, and patient-specific body parameters. This tendency complements the overall action to develop digital health options and utilize the data related to patient care and treatment that is optimized. Such devices (smart wearable injectors) are of great advantage to people particularly those with chronic illnesses because they offer real-time data and thus efficient preventive care.
Moreover, the arena of wearable injectors also views new design ideas and advancements. Alongside the manufacturers, there is technology coming out that is smaller, more discreet and user-friendly, thus, in total, enhance the patient experience. Technology including easy-to-use interfaces, audible reminders and ergonomic design play a role in use of wearable injectors across patients in all age groups and in those of different degrees of proficiency in technology. Thus, the main aims of this trend are centered on the idea that better user-oriented design can lead to positive patient attitudes to the utilization of wearable injector technologies.
In addition to this, there is a substantial trend about the design of injectors for slowly viscous drugs and biologicals that can be used by patients themselves at home. Injectors belonging to the old school may be facing problems in delivering thick formulations but because of the advanced mechanics and materials of wearable injectors, these injectors are capable of administering high viscosity medicines. The development of automation and multidose injection systems has followed the rise of biologics and injectable treatments, thus providing a flexible solution for the administration of different types of drugs through one delivery method.
Other big trend is the increasing use of wearable injector to other therapeutic injections. Initially invented for the insulin management in patients with diabetes mellitus, wearable injectors are now under development and deployed for the administration of drugs in other spheres such as oncology, cardiovascular diseases, and autoimmune disorders among others. This diversification mirrors the blankness in the applications of wearable injector technology and the possibility of its use in different medical subgroups.
Report Attribute/Metric | Details |
---|
The wearable injectors market has been segmented into type, usage, mechanism of action, therapeutic area, and end-user.
The wearable injectors market, on the basis of type, has been segmented into on-body wearable injectors, off-body wearable injectors, and hand-held wearable injectors.
The wearable injectors market, by usage, has been segmented into disposable and semi-reusable.
The market, by mechanism of action, has been segmented into spring based, motor driven, rotary pump, expanding battery, pressurized gas, and collapsible reservoir.
The market, by therapeutic area, has been segmented into oncology, infectious diseases, cardiovascular diseases, autoimmune diseases, diabetes, and others.
The market, by end-user, has been segmented into hospitals, clinics, homecare, ambulatory surgery centers, others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The wearable injectors market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European wearable injectors market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.Â
The wearable injectors market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The wearable injectors market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key players
West Pharmaceutical Services, Inc., Valeritas, Inc., Eli Lilly and Company, YPSOMED, Amgen Inc., Becton, Dickinson and Company (BD), CeQur SA, SteadyMed Therapeutics, Inc., BioSpace, Enable Injections, and Sensile Medical AG are some of the key players in the wearable injectors market.
Regional Market Summary
Wearable Injectors Market Share (%), by Region
Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)
Geographically, the Americas is anticipated to dominate the wearable injectors market owing to a well-developed healthcare sector, rising prevalence of autoimmune and chronic disease and growing healthcare expenditure. According to a report published by American Autoimmune Related Diseases Association (AARDA) in April 2017, in the US approximately 50 million people i.e. nearly 20% population suffer from autoimmune diseases. Additionally, government funding in this region contributes to the growth of the market.
Europe is expected to hold the second largest position in the wearable injectors market. The market growth in this region is attributed to the growing prevalence of chronic diseases, the availability of funds for research, and increasing healthcare expenditure. According to a report published by the NSD Alliance in July 2017, 1/3rd of the European population above the age of 15 years suffer from a chronic disease.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, rising prevalence of chronic diseases like diabetes, cardiovascular diseases and increasing government funding for the healthcare sector. According to a study published in the Asian Pacific Journal of Tropical Biomedicine journal in 2014, it was estimated that about 150 million diabetic patients reside within the region, out of which more than 95% have type 2 diabetes mellitus.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.Recent Development
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)